Hanson & Doremus Investment Management’s SPDR S&P Biotech ETF XBI Stock Holding History
Bought
Maintained
Sold
Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
---|---|---|---|---|---|---|---|---|
2025
Q2 | $108K | Sell |
1,300
-355
| -21% | -$29.5K | 0.01% | 255 |
|
2025
Q1 | $134K | Sell |
1,655
-1,924
| -54% | -$156K | 0.02% | 224 |
|
2024
Q4 | $322K | Sell |
3,579
-1,346
| -27% | -$121K | 0.05% | 146 |
|
2024
Q3 | $487K | Sell |
4,925
-2,877
| -37% | -$284K | 0.08% | 110 |
|
2024
Q2 | $723K | Sell |
7,802
-1,107
| -12% | -$103K | 0.12% | 90 |
|
2024
Q1 | $845K | Sell |
8,909
-4,697
| -35% | -$446K | 0.15% | 84 |
|
2023
Q4 | $1.22M | Sell |
13,606
-9,706
| -42% | -$867K | 0.23% | 72 |
|
2023
Q3 | $1.7M | Sell |
23,312
-544
| -2% | -$39.7K | 0.35% | 60 |
|
2023
Q2 | $1.99M | Buy |
23,856
+1,534
| +7% | +$128K | 0.41% | 50 |
|
2023
Q1 | $1.7M | Buy |
22,322
+351
| +2% | +$26.7K | 0.38% | 56 |
|
2022
Q4 | $1.82M | Buy |
21,971
+1,885
| +9% | +$156K | 0.39% | 58 |
|
2022
Q3 | $1.59M | Buy |
20,086
+4,468
| +29% | +$354K | 0.41% | 54 |
|
2022
Q2 | $1.16M | Buy |
15,618
+2,405
| +18% | +$179K | 0.28% | 72 |
|
2022
Q1 | $1.19M | Buy |
13,213
+1,472
| +13% | +$132K | 0.26% | 73 |
|
2021
Q4 | $1.32M | Buy |
11,741
+1,094
| +10% | +$123K | 0.28% | 65 |
|
2021
Q3 | $1.34M | Buy |
10,647
+2,055
| +24% | +$258K | 0.31% | 65 |
|
2021
Q2 | $957K | Sell |
8,592
-760
| -8% | -$84.7K | 0.29% | 70 |
|
2021
Q1 | $1.27M | Buy |
9,352
+530
| +6% | +$71.9K | 0.29% | 73 |
|
2020
Q4 | $1.24M | Buy |
8,822
+230
| +3% | +$32.4K | 0.31% | 63 |
|
2020
Q3 | $957K | Buy |
8,592
+1,461
| +20% | +$163K | 0.29% | 70 |
|
2020
Q2 | $798K | Sell |
7,131
-93
| -1% | -$10.4K | 0.25% | 80 |
|
2020
Q1 | $559K | Buy |
7,224
+1,606
| +29% | +$124K | 0.19% | 94 |
|
2019
Q4 | $534K | Buy |
5,618
+1,259
| +29% | +$120K | 0.15% | 110 |
|
2019
Q3 | $332K | Buy |
4,359
+4,230
| +3,279% | +$322K | 0.1% | 133 |
|
2019
Q2 | $11K | Buy |
+129
| New | +$11K | ﹤0.01% | 411 |
|